Vanda Pharmaceuticals’ (VNDA) Buy Rating Reaffirmed at Oppenheimer

Oppenheimer restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note released on Monday morning.

Several other equities analysts have also issued reports on VNDA. Piper Jaffray Companies increased their target price on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an overweight rating in a research note on Thursday, September 14th. Zacks Investment Research lowered Vanda Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Thursday, October 5th. ValuEngine lowered Vanda Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, October 26th. Finally, BidaskClub raised Vanda Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, December 22nd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $21.50.

Vanda Pharmaceuticals (NASDAQ VNDA) traded down $0.05 during midday trading on Monday, hitting $14.20. The stock had a trading volume of 607,170 shares, compared to its average volume of 618,500. The stock has a market cap of $628.99, a PE ratio of -44.38 and a beta of 1.29. Vanda Pharmaceuticals has a fifty-two week low of $11.90 and a fifty-two week high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). The business had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The company’s revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.01) EPS. equities analysts forecast that Vanda Pharmaceuticals will post -0.44 earnings per share for the current fiscal year.

In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 9,155 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total value of $140,529.25. Following the sale, the chief financial officer now owns 144,721 shares of the company’s stock, valued at approximately $2,221,467.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the sale, the insider now directly owns 1,031,848 shares in the company, valued at approximately $15,787,274.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 209,483 shares of company stock worth $3,205,205. 7.60% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Vanda Pharmaceuticals by 7.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock valued at $43,698,000 after purchasing an additional 186,548 shares in the last quarter. Macquarie Group Ltd. raised its position in Vanda Pharmaceuticals by 10.9% in the 3rd quarter. Macquarie Group Ltd. now owns 1,890,085 shares of the biopharmaceutical company’s stock valued at $33,833,000 after purchasing an additional 186,526 shares in the last quarter. State Street Corp raised its position in Vanda Pharmaceuticals by 2.9% in the 2nd quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock valued at $26,380,000 after purchasing an additional 46,299 shares in the last quarter. Rothschild Asset Management Inc. acquired a new stake in Vanda Pharmaceuticals in the 3rd quarter valued at about $23,491,000. Finally, Renaissance Technologies LLC raised its position in Vanda Pharmaceuticals by 16.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,097,950 shares of the biopharmaceutical company’s stock valued at $17,897,000 after purchasing an additional 158,700 shares in the last quarter. 88.43% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/09/vanda-pharmaceuticals-vnda-buy-rating-reaffirmed-at-oppenheimer.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply